AEZS AEterna Zentaris Inc. gains 30% Jan 27, 2020

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which is in Phase III clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer, as well as completed Phase II clinical trial for the treatment of ovarian and prostate cancer; and MACRILEN, which is in Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development; and AEZS-120 for the treatment of prostate cancer. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.http://www.priceseries.com/trade/AEZS-AEterna-Zentaris-Inc-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2020010320200127.html